Abstract
The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Current Topics in Medicinal Chemistry
Title: Subclassification and Nomenclature of α- and β-Adrenoceptors
Volume: 7 Issue: 2
Author(s): J. Paul Hieble
Affiliation:
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Abstract: The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Export Options
About this article
Cite this article as:
Hieble J. Paul, Subclassification and Nomenclature of α- and β-Adrenoceptors, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318172
DOI https://dx.doi.org/10.2174/156802607779318172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biogenic Amines (BAs) in Meat Products, Regulatory Policies, and Detection Methods
Current Nutrition & Food Science Complications of the Chest Wall and the Respiratory System After Surgery and Functional Performance
Current Respiratory Medicine Reviews Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Effects of Evolocumab on Cardiovascular Events
Current Cardiology Reviews Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Hepatotoxic Effect of <i>Lafoensia pacari</i> A. St. Hil. (Lythraceae) on a Diet-Induced Obese Mice Model
Protein & Peptide Letters Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Sleep Apnea and Atrial Fibrillation; 2012 Update
Current Cardiology Reviews Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry UHPLC-ESI-QToF Analysis of Trandolapril and Verapamil Hydrochloride in Dosage Form and Spiked Human Plasma Using Solid Phase Extraction: Stability Indicating Assay Method
Current Pharmaceutical Analysis Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Subject Index To Volume 3
Current Neurovascular Research Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Oxidative Stress and Endothelial Function: Therapeutic Interventions
Recent Patents on Cardiovascular Drug Discovery